Management of Patients With Advanced Prostate Cancer: Establishment ofTreatment Guidelines Through Prostate Cancer Summit (PCAS) 2016Composed of Korean Prostate Cancer Experts
10.22465/kjuo.2020.18.2.124
- Author:
Chun Tae JANG
1
;
Hyung Joon KIM
;
Myung Ki KIM
;
Sung Woo PARK
;
Seung Chol PARK
;
Jae Young PARK
;
Dong Hyeon LEE
;
Seung Hwan LEE
;
Hwang Gyun JEON
;
Jae Hoon CHUNG
;
Hyeon JEONG
;
Moon Ki JO
;
Sung-Hoo HONG
;
Cheol KWAK
;
Ji Youl LEE
;
Dong Deuk KWON
;
Choung-Soo KIM
;
Seong Soo JEON
Author Information
1. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Publication Type:Original Article
- From:Korean Journal of Urological Oncology
2020;18(2):124-139
- CountryRepublic of Korea
-
Abstract:
Purpose:The Advanced Prostate Cancer Consensus Conference (APCCC) 2015 was based on topics withcontroversy in the field of advanced prostate cancer. To understand the Korean urologists perspective regardingthe issues, we have conducted a questionnaire named Prostate Cancer Summit (PCAS) 2016, with 9 importantsubtopics.
Materials and Methods:Total 9 subtopics have been decided and questions were developed regarding eachsubtopic. The questions were based on that of APCCC 2015 and translated into Korean for better understanding.Total 51 panelists have voted online on 85 different questions.
Results:The survey concluded that testosterone should be measured as a diagnostic criterion for castrationresistance prostate cancer (CRPC) and that consensus was reached on issues such as the use of androgenreceptor pathway inhibitors in the treatment of predocetaxel and postdocetaxel in CRPC patients. In addition,76% of the participants agreed that imaging tests were needed before new treatment in CRPC patients, anda majority of participants agreed that periodic imaging tests are necessary regardless of symptoms during treatmentfor CRPC. However, some issues, such as the use of prostate-specific antigen-based triggers for remediationin CRPC patients, the endocrine manipulation in nonmetastatic CRPC patients, and the onset of treatment inasymptomatic metastatic CRPC patients, were not agreed.
Conclusions:The results from PCAS 2016 has addressed some of the issues with controversy. Although thevoting results are subjective, it will help guide treatment decisions in topics with less evidence.
